In a recently published study, researchers sought to elucidate if 2 treatments modulated immune response or not, despite the available evidence being conflicting. The method that made the difference and allowed them to reach their conclusions, is based on 16 human cytokines using multiplex immunoassays with the Quansys technology.

In a previous post, I introduced the C-series multiplex profiling technology from Raybiotech, a smart way to multiplex your western blot while saving time and sample volume, and decreasing the cost of your experiment.

Indeed, one blot for multiple targets processed at once is a nice way to boost your protein profiling studies!

I just wanted to highlight in this post, that on top of the standard species models like human, mouse and rat, these C-series are also available for many other models. With 15 different species to select from, RayBiotech is leading the way for immunoassay kit species diversity.

Monoclonal antibodies (mAbs) are used as immunotherapeutics to treat cancer and other diseases, and either aim to induce target cell destruction or immune cell activation. After binding to their cognate antigens, mAbs engage Fc gamma receptor  (FcγR), localised on the surface of the Immune cells, and identified by many research groups as regulator of mAbs activity. To help researchers working on immunotherapeutic mAbs development, BPS Bioscience have developed a new CHO K1 cell line stably expressing full length human FcGR2B.

My colleague Ana introduced in a previous post (3 years ago already!) a selection of the most popular anti-tag antibodies among the research community. I must say that they remain extremely popular, showing their robustness over time. In this post, I would like to focus on anti-RFP antibodies and anti-GFP antibodies, looking at a selection of high quality, fully validated, reliable tools.